| ［1］ |
中华医学会血液学分会造血干细胞应用学组, 中国抗癌协会血液病转化委员会. 慢性移植物抗宿主病（cGVHD）诊断与治疗中国专家共识（2021年版）［J］. 中华血液学杂志, 2021,42（4）:265-275. doi: 10.3760/cma.j.issn.0253-2727.2021.04.001.
|
| ［2］ |
Escamilla Gómez V, García-Gutiérrez V, López Corral L, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study［J］. Bone Marrow Transplant, 2020,55（3）:641-648. doi: 10.1038/s41409-019-0731-x.
|
| ［3］ |
张会, 申徐良, 苏飞跃. 芦可替尼治疗移植物抗宿主病的研究进展［J］. 临床内科杂志, 2021,38（7）:499-501. doi: 10.3969/j.issn.1001-9057.2021.07.021.
|
| ［4］ |
González Vicent M, Molina B, González de Pablo J, et al. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results［J］. Am J Hematol, 2019,94（3）:319-326. doi: 10.1002/ajh.25376.
|
| ［5］ |
Neumann T, Schneidewind L, Weigel M, et al. Ruxolitinib for therapy of graft-versus-host disease［J］. Biomed Res Int, 2019,2019:8163780. doi: 10.1155/2019/8163780.
|
| ［6］ |
黄晓雯, 鲍协炳, 仇惠英, 等. 小剂量芦可替尼治疗38例急慢性移植物抗宿主病的疗效观察［J］. 中华器官移植杂志, 2019,40（12）:749-752. doi: 10.3760/cma.j.issn.0254-1785.2019.12.010.
|
| ［7］ |
Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease［J］. N Engl J Med, 2021,385（3）:228-238. doi: 10.1056/NEJMoa2033122.
|
